51298-61-4

Upstream product

• 57818-19-6 N-trityl dibenzyl L-aspartate 
• 124-41-4 sodium methylate 
• 7362-93-8 (S)-3-amino-4-(benzyloxy)-4-oxobutanoic acid 
• 3262-72-4 (S)-N-(tert-butoxycarbonyl)serine 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 100-51-6 benzyl alcohol 
• 67-56-1 methanol 
• 2791-79-9 dibenzyl L-aspartate 

Downstream Products

• 122701-32-0 N-(O-methyl-N-trityl-L-α-glutamyl)-L-aspartic acid-4-methyl ester 
• 144876-82-4 4-methyl-1-(phenylmethyl) -N-amino>ethyl>amino>ethyl>amino>carbonyl>glycyl>-L-aspartate 
• 144876-83-5 4-methyl-1-(phenylmethyl) -N-amino>ethyl>amino>ethyl>amino>carbonyl>glycyl>-L-aspartate 
• 144876-84-6 4-methyl-1-(phenylmethyl) -N-<<1-<<<<1-(1H-indol-3-ylmethyl)-2-oxo-2-<<2-phenyl-2-<<(phenylmethoxy)carbonyl>amino>ethyl>amino>ethyl>amino>carbonyl>amino>cyclohexyl>carbonyl>-L-aspartate 
• 144876-85-7 4-methyl-1-(phenylmethyl) -N-<<1-<<<<1-(1H-indol-3-ylmethyl)-1-methyl-2-oxo-2-<<2-phenyl-2-<<(phenylmethoxy)carbonyl>amino>ethyl>amino>ethyl>amino>carbonyl>amino>cyclohexyl>carbonyl>-L-aspartate 
• 1007880-96-7 (S)-1-benzyl 4-methyl 2-(9-phenyl-9H-fluoren-9-ylamino)succinate 
• 144876-91-5 methyl <7S-(7α,10β,14α)>-14-(1H-indol-3-ylmethyl)-14-methyl-2,5,8,13-tetraoxo-10-phenyl-1,3,6,9,12-pentaazacyclotetradecane-7-acetate 
• 144876-86-8 4-methyl -N--1-(1H-indol-3-ylmethyl)-2-oxo-ethyl>amino>carbonyl>glycyl>-L-aspartate 
• 144876-92-6 methyl <10R-(10α,14β,17α)>-10-(1H-indol-3-ylmethyl)-8,11,16,19-tetraoxo-14-phenyl-7,9,12,15,18-petaazaspiro<5,13>nonadecane-17-acetate 
• 144876-87-9 4-methyl -N--1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl>amino>carbonyl>glycyl>-L-aspartate 
• 144876-93-7 methyl <10R-(10α,14β,17α)>-10-(1H-indol-3-ylmethyl)-10-methyl-8,11,16,19-tetraoxo-14-phenyl-7,9,12,15,18-pentaazaspiro<5,13>nonadecane-17-acetate 
• 144876-88-0 4-methyl -N-<<1-<<<<2-<(2-amino-2-phenylethyl)amino>-1-(1H-indol-3-ylmethyl)-2-oxoethyl>amino>carbonyl>amino>cyclohexyl>carbonyl>-L-aspartate 
• 144876-89-1 4-methyl -N-<<1-<<<<2-<(2-amino-2-phenylethyl)amino>-1-(1H-indol-3-ylmethyl)-1-methyl-2-oxoethyl>amino>carbonyl>amino>cyclohexyl>carbonyl>-L-aspartate 
• 482631-95-8 (2S,3S)-benzyl 4-hydroxy-3-methyl-2-(9-phenyl-9H-fluoren-9-ylamino)butanoate 

Relevant academic research and scientific papers

Diboronic Acid Anhydride-Catalyzed Direct Peptide Bond Formation Enabled by Hydroxy-Directed Dehydrative Condensation

We report the catalytic direct peptide bond formations via dehydrative condensation of β-hydroxy-α-amino acids, affording the serine, threonine, or β-hydroxyvaline-derived peptides in high to excellent yields with high functional group tolerance, minimum epimerization, and excellent chemoselectivity. The key to the success of these atom-economical transformations is the use of diboronic acid anhydride catalyst for the hydroxy-directed reactions.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.